- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Founded in 2013 in Paris, by the French immunologist Philippe Pouletty.
In 2015, Abivax launched its initial public offering on the stock market Euronext in Paris, raising EUR 57.7m, a record amount for a French biotechnology company on the Euronext in Paris.
In October 2023, Abivax launched its initial public offering (IPO) on the Nasdaq Global Market in the US, raising EUR 232m, the largest ever US IPO of a French listed biotech.
Initially, Abivax focused on the development of a novel treatment in HIV with lead drug candidate obefazimod. As the molecule showed a strong anti-inflammatory effect in preclinical models, Abivax decided to conduct a Phase 2a clinical study in ulcerative colitis, an inflammatory bowel disease (IBD). Based on the promising results of this clinical study in ulcerative colitis, the company decided to shift its focus towards the treatment of chronic inflammatory diseases.
August 2025, the stock price of Abivax surged by around 580% following dual Phase III success in ulcerative colitis. Hedge Funds who were invested in the company made substantial gains.
July 2026, the Company issued 7,360,000 American Depositary Shares (ADSs), raising $920 million, equivalent to approximately 807.4 million euros.